eligibility_summary
Adults 18–75 with recurrent/metastatic gynecologic cancer lacking/failed standard therapy: ECOG 0–1, ≥1 RECIST lesion, survival ≥3 mo, prior toxicities ≤G1, LVEF ≥50%, adequate organs/coagulation, urine protein ≤2+ or ≤1000 mg/24h, tumor tissue available, contraception/negative pregnancy. Exclude: recent therapy, major cardiac/QT/arrhythmia, active autoimmune/ILD/lung disease, uncontrolled HTN/glucose, thrombosis, CNS mets/effusions, antibody allergy, vessel invasion, prior transplant, anthracycline >360 mg/m², HIV/TB/active HBV/HCV, recent infection, recent trial, or other unsuitability.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Trial NCT05803018 tests BL-B01D1 (izalontamab brengitecan, BMS-986507), an investigational antibody–drug conjugate (ADC) given IV to patients with recurrent/metastatic gynecologic and other solid tumors. Mechanism: a tumor‑targeting monoclonal antibody binds a surface antigen (not specified in the entry), is internalized, and releases a “-tecan” payload (brengitecan), a camptothecin/topoisomerase I inhibitor, causing DNA damage and tumor cell death. Targets: antigen‑expressing tumor cells, key pathways include receptor-mediated internalization and DNA replication/repair via Topoisomerase I (DNA damage response).